Traws Pharma, Inc.

As of November 14, 2025, Traws Pharma, Inc. is considered an attractive investment opportunity due to its undervalued status, strong ROE of 939.05%, and favorable valuation ratios, despite a year-to-date decline of 76.58%, while showing a robust three-year return of 136.36%.

As of November 14, 2025, Traws Pharma, Inc. is considered an attractive investment due to its undervalued metrics, including a P/B ratio of 1.53 and a P/E ratio of 0.2145, especially when compared to peers like Catalyst Biosciences and Elutia, while also showing no negative returns relative to the S&P 500.

As of November 14, 2025, Traws Pharma, Inc. is considered attractively valued with a low P/E ratio and high ROE, but has faced significant challenges reflected in a year-to-date return of -75.56%, raising market skepticism despite its strong valuation metrics.

As of June 2, 2025, Traws Pharma, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators present mixed signals, and the stock has underperformed the S&P 500 with a year-to-date return of -76.80%.

As of August 14, 2025, Traws Pharma, Inc. has improved its valuation outlook to attractive, showing signs of being undervalued with a low P/E ratio of 0, an EV to EBIT ratio of 0.14, and an impressive ROE of 939.05%, despite a challenging stock performance with a year-to-date return of -76.80% compared to the S&P 500's 12.22%.

As of August 12, 2020, Traws Pharma, Inc. is considered undervalued with extreme financial ratios, including a P/E ratio of 0 and an EV to EBIT of 0.14, reflecting significant market concerns about its financial health and future prospects, especially as it has underperformed the S&P 500 by -82.55% year-to-date.

As of June 2, 2025, Traws Pharma, Inc. exhibits a mildly bearish trend due to conflicting indicators, with daily moving averages showing bearishness and weekly signals suggesting mild bullishness, resulting in a lack of strong bullish momentum.

As of March 2022, the management team of Traws Pharma, Inc. includes Mr. James Marino (Chairman), Dr. Steven Fruchtman (President and CEO), and Directors Dr. Henry Bienen, Dr. Jerome Groopman, Dr. Viren Mehta, Ms. Terri Shoemaker, and Mr. Jack Stover. They oversee the company's operations and strategic direction.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs for cancer treatment. As of March 2025, it has a market cap of $9.24 million, with net sales of $0 million and a net profit of $15 million.

As of Jun 18, Traws Pharma, Inc. has a market capitalization of 9.24 million and reported net sales of 0.24 million with a net profit of -34.60 million over the last four quarters. The company's shareholder's funds are -31.63 million, with total assets of 24.96 million.